HLS Market Capitalization from 2010 to 2026
| HLS Stock | CAD 4.50 0.01 0.22% |
Check HLS Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HLS Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 13.2 M, Interest Expense of 12.2 M or Total Revenue of 55.7 M, as well as many indicators such as Price To Sales Ratio of 1.19, Dividend Yield of 0.0102 or PTB Ratio of 0.73. HLS financial statements analysis is a perfect complement when working with HLS Therapeutics Valuation or Volatility modules.
HLS | Market Capitalization |
Evaluating HLS Therapeutics's Market Capitalization across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into HLS Therapeutics's fundamental strength.
Latest HLS Therapeutics' Market Capitalization Growth Pattern
Below is the plot of the Market Cap of HLS Therapeutics over the last few years. It is HLS Therapeutics' Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HLS Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 141.27 M | 10 Years Trend |
|
Market Cap |
| Timeline |
HLS Market Capitalization Regression Statistics
| Arithmetic Mean | 150,071,021 | |
| Geometric Mean | 77,898,118 | |
| Coefficient Of Variation | 112.56 | |
| Mean Deviation | 137,170,720 | |
| Median | 69,418,114 | |
| Standard Deviation | 168,918,936 | |
| Sample Variance | 28533.6T | |
| Range | 554.5M | |
| R-Value | 0.34 | |
| Mean Square Error | 26923.3T | |
| R-Squared | 0.12 | |
| Significance | 0.18 | |
| Slope | 11,363,909 | |
| Total Sum of Squares | 456537.7T |
HLS Market Capitalization History
About HLS Therapeutics Financial Statements
HLS Therapeutics investors utilize fundamental indicators, such as Market Capitalization, to predict how HLS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
HLS Therapeutics Inc., a specialty pharmaceutical company, focuses on acquiring and commercializing pharmaceutical products in the specialty central nervous system and cardiovascular markets. It has license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. HLS THERAPEUTICS operates under Drug Manufacturers - Specialty Generic classification in Canada and is traded on Toronto Stock Exchange. It employs 46 people.
Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.